Allianz SE Trims Stake in DexCom, Inc. $DXCM

Allianz SE lowered its holdings in DexCom, Inc. (NASDAQ:DXCM) by 83.4% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 8,636 shares of the medical device company’s stock after selling 43,425 shares during the period. Allianz SE’s holdings in DexCom were worth $581,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Brighton Jones LLC raised its stake in DexCom by 257.7% in the fourth quarter. Brighton Jones LLC now owns 16,582 shares of the medical device company’s stock valued at $1,290,000 after purchasing an additional 11,946 shares in the last quarter. Integrated Wealth Concepts LLC grew its stake in DexCom by 6.3% in the 1st quarter. Integrated Wealth Concepts LLC now owns 3,329 shares of the medical device company’s stock worth $227,000 after buying an additional 196 shares in the last quarter. Empowered Funds LLC increased its holdings in shares of DexCom by 5.4% in the 1st quarter. Empowered Funds LLC now owns 8,446 shares of the medical device company’s stock worth $577,000 after buying an additional 436 shares during the last quarter. Focus Partners Wealth increased its holdings in shares of DexCom by 13.2% in the 1st quarter. Focus Partners Wealth now owns 7,218 shares of the medical device company’s stock worth $493,000 after buying an additional 841 shares during the last quarter. Finally, Focus Partners Advisor Solutions LLC purchased a new stake in shares of DexCom during the 2nd quarter valued at $317,000. Hedge funds and other institutional investors own 97.75% of the company’s stock.

DexCom Stock Performance

Shares of NASDAQ:DXCM opened at $73.43 on Friday. The company has a current ratio of 1.88, a quick ratio of 1.59 and a debt-to-equity ratio of 0.45. The company has a 50-day moving average price of $70.24 and a 200-day moving average price of $69.15. The company has a market cap of $28.26 billion, a price-to-earnings ratio of 34.97, a price-to-earnings-growth ratio of 1.43 and a beta of 1.49. DexCom, Inc. has a 12 month low of $54.11 and a 12 month high of $89.98.

DexCom (NASDAQ:DXCM) last posted its earnings results on Thursday, February 12th. The medical device company reported $0.68 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.65 by $0.03. The company had revenue of $1.26 billion for the quarter, compared to analysts’ expectations of $1.25 billion. DexCom had a return on equity of 32.12% and a net margin of 17.94%.DexCom’s quarterly revenue was up 13.1% on a year-over-year basis. During the same period last year, the firm earned $0.45 earnings per share. As a group, equities analysts anticipate that DexCom, Inc. will post 2.03 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on the stock. Wells Fargo & Company cut their target price on shares of DexCom from $93.00 to $85.00 and set an “overweight” rating for the company in a research report on Friday, February 13th. Sanford C. Bernstein reaffirmed an “outperform” rating and set a $86.00 price target (up from $84.00) on shares of DexCom in a research note on Friday, January 9th. BTIG Research reiterated a “buy” rating and set a $85.00 price objective on shares of DexCom in a research report on Wednesday. Truist Financial reissued a “buy” rating and set a $80.00 price objective (down from $82.00) on shares of DexCom in a report on Tuesday, February 17th. Finally, UBS Group cut their target price on DexCom from $106.00 to $95.00 and set a “buy” rating for the company in a research note on Monday, November 3rd. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating, four have issued a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $85.18.

DexCom Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.